# A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

> **NCT04617925** · PHASE2 · COMPLETED · sponsor: **Stichting European Myeloma Network** · enrollment: 35 (actual)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** Belantamab mafodotin

## Key facts

- **NCT ID:** NCT04617925
- **Lead sponsor:** Stichting European Myeloma Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-26
- **Primary completion:** 2025-07-17
- **Final completion:** 2025-07-17
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617925, "A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04617925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*